Arrowhead's REDEMPLO gets UK marketing authorization for FCS; NICE recommends NHS funding

Arrowhead Pharmaceuticals' REDEMPLO received UK marketing authorization for familial chylomicronaemia syndrome. NICE recommends NHS funding in England and Wales for eligible adults with genetically confirmed FCS.

Detected & updated continuously · Source: Nebula